Liege, Belgium — September 3, 2025 — Leads & Copy — Allegro NV, a biomedical company focused on nanotechnology-based treatments for degenerative joint disease, has appointed Stephan Crokaert as Chief Operating Officer.
Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings over 35 years of strategic and commercial experience in life sciences. The appointment strengthens Allegro’s management team and sharpens its focus on the clinical and commercial development of hydrocelin, a potential first-in-class injectable treatment for osteoarthritis. Allegro plans to advance hydrocelin into clinical trials in 2026.
CEO Lucas Decuypere said the appointment comes at a crucial time as the company prepares its treatment for clinical trials.
Allegro successfully raised €2 million in new funding in July. The company completed the installation of a manufacturing device in August and presented positive preclinical data in April.
Lucas Decuypere, Chief Executive Officer, info@allegro.bio
Mary-Ann Chang, Cohesion Bureau, +44 7483 284 853, mary-ann.chang@cohesionbureau.com
Douwe Miedema, Cohesion Bureau, +352 621 562 764, douwe.miedema@cohesionbureau.com
Source: Allegro NV
